Listing 1 - 10 of 29 | << page >> |
Sort by
|
Choose an application
Choose an application
"Diabetes remains one of the main causes, in the western world, of legal blindness, end stage renal disease, and amputation, despite the implementation of tight glycemic control and the great progress in the management and care of our patients. In the perspective that clinical and basic-science knowledge are fundamental to clinicians as well as to researchers, this book is a valuable resource by integrating clinical information and research frontlines of the microvascular complications of diabetes. It will provide up-to-date diagnostic criteria, classifications, and therapeutic approaches and recent discoveries on mechanisms of disease, experimental therapeutic agents, and biomarkers of disease. The ultimate goal of this book is to provide a useful and handy tool to professionals and students in the field of diabetes and its microvascular complications. Will provide a much-needed resource synthesizing research and clinical applications to treating microvascular complications of diabetes. Covers all relevant microvascular systems. Provides current diagnostic criteria, classifications, and therapeutic approaches, as well as recent discoveries on the mechanisms of disease, experimental therapeutic agents, and biomarkers of disease"--
Diabetes. --- Diabetic angiopathies. --- Diabetic Angiopathies --- Diabetes Mellitus
Choose an application
Choose an application
Choose an application
Choose an application
Diabetes Mellitus --- Diabetic Angiopathies --- diagnosis --- therapy
Choose an application
Type 2 diabetes (T2DM) is associated with a high cardiovascular risk. Therefore, there is a real need for a preventive treatment to limit the occurrence of cardiovascular complications of T2DM. Thus, drugs that allow a glycemic control and provide a cardio-protective protection are emerging. Indeed, clinical trials have resulted in new drugs associated with a cardiovascular benefit among patients with T2DM who were at high cardiovascular risk: these are inhibitors of co-transporter sodium-glucose type2 (SGLT2) at the renal level with empagliflozin and canagliflozin as well as glucagon-like peptide 1 (GLP-1) analogues with liraglutide and semaglutide. Le diabète de type 2 (DT2) est associé à un risque cardio-vasculaire élevé. Par conséquent, il existe un réel besoin de traitements préventifs pour limiter la survenue des complications-vasculaires du TD2. C’est ainsi que des médicaments qui permettent un contrôle glycémique et qui confèrent une protection cardio-protectrice voient le jour. En effet, des essais cliniques ont abouti à de nouveaux médicaments associés à un bénéfice cardio-vasculaire parmi les patients atteints par le DT2 et qui présentaient un risque cardio-vasculaire élevé : il s’agit des inhibiteurs du cotransporteur sodium-glucose de type 2 (SGLT2) au niveau rénal avec l’empagliflozine et la canagliflozine aonsi que les analogues du glucagon-like-peptide-1 (GLP-1) avec le liraglutide et le semaglutide.
Diabetes Mellitus, Type 2 --- Diabetic Angiopathies --- Cardiovascular Diseases
Choose an application
Diabetes Mellitus --- Diabetic Angiopathies --- Diabetes Mellitus, Type 2 --- epidemiology --- mortality
Choose an application
Diabetes. --- Diabetes --- Diabetic angiopathies. --- Diabetes Complications --- Diabetic Angiopathies --- Diabète --- Angiopathies diabétiques. --- Complications. --- Complications et séquelles.
Choose an application
Microangiopathies are pathological processes causing degenerative disorders of small vessels. The circulatory problems caused by microangiopathies may be responsible for failure of individual or multiple organs. These pathological processes are indeed one of the most common disorders characterized by high morbility and mortality in the affected patients. Many studies have revealed very complicated processes both at cellular and molecular level. However, much work remains to define the diversity of different pathogenetic mechanisms leading to microangiopathic disorders to provide appropriate prevention and treatment strategies. The aim of this volume is providing illustrative examples of relevant mechanisms responsible for different forms of microangiopathies and how this body of evidences can be harnessed to define new strategies of therapeutic intervention.
Diabetic angiopathies. --- Diabetic vascular complications --- Diabetic vascular diseases --- Blood-vessels --- Diabetes --- Diseases --- Complications --- Endocrinology
Listing 1 - 10 of 29 | << page >> |
Sort by
|